Komori
Hodogaya Chemical (4112) · FactAdvanced

Continued R&D Investment

First written in FY2017-Q1. 15 of 29 entries say "Restated". Latest entry: FY2026.

29entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q1 – FY2021-Q2AdvancedFY2023-Q2 – FY20252016: 220162017: 320172018: 320182019: 420192020: 320202021: 120212022: 420222023: 320232024: 220242025: 220252026: 22026
Same theme, other companies
Continuation of Company-wide R&D Activities and Resource InvestmentA theme 216 companies write about · 0 as a headwind · 229 as a tailwind

59 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 186 companies compared. The sentences above are computed from all 186.Comparing 200 of the theme's 231 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Research and development expenses for the current fiscal year for the Group as a whole were ¥5,924 million.」

    Research and development expenses increased from ¥5,638 million in the previous fiscal year to ¥5,924 million, confirming an expansion in full-year research and development investment.
  2. 2026-05-15AdvancedEarnings

    「R&D expenses increased from ¥5,638 million to ¥5,924 million.」

    Full-year results confirmed an increase in R&D expenses, indicating an expansion in R&D spending from the previous fiscal year.
  3. FY2026-H1SoftenedAnnual report

    「Total research and development expenses for the current interim consolidated accounting period were ¥2,848 million.」

    Research and development expenses decreased from ¥2,889 million in the same period of the previous year to ¥2,848 million, but ongoing research and development spending was maintained.
  4. FY2025AdvancedAnnual report

    「Research and development expenses for the current fiscal year for the Group as a whole were ¥5,638 million.」

    Research and development expenses increased from ¥5,011 million in the previous fiscal year to ¥5,638 million, confirming an expansion in full-year research and development investment.
  5. FY2025-H1AdvancedAnnual report

    「Total research and development expenses for the current interim consolidated accounting period were ¥2,889 million.」

    Research and development expenses increased from ¥2,312 million in the same period of the previous year to ¥2,889 million, with the expansion of ongoing research and development spending disclosed.
  6. FY2024-Q3AdvancedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥3,677 million.」

    Research and development expenses increased from ¥3,528 million in the same period of the previous year to ¥3,677 million, indicating an expansion in ongoing research and development spending.
  7. FY2024-Q2AdvancedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥2,312 million.」

    Research and development expenses increased from ¥2,256 million in the same period of the previous year to ¥2,312 million, with ongoing research and development spending disclosed.
  8. FY2024-Q1AdvancedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥1,124 million.」

    Research and development expenses increased from ¥1,015 million in the same period of the previous year to ¥1,124 million, with ongoing research and development spending disclosed.
  9. FY2023-Q3AdvancedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥3,528 million.」

    Research and development expenses increased from ¥2,815 million in the same period of the previous year to ¥3,528 million, indicating an expansion in ongoing research and development spending.
  10. FY2023-Q2AdvancedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥2,256 million.」

    Research and development expenses increased from ¥1,746 million in the same period of the previous year to ¥2,256 million, with ongoing research and development spending disclosed.
  11. FY2023-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥1,015 million.」

    Ongoing research and development spending was disclosed at ¥1,015 million for the current first-quarter cumulative period.
  12. FY2022AdvancedAnnual report

    「Research and development expenses for the current fiscal year for the Group as a whole were ¥3,859 million.」

    Full-year research and development expenses were disclosed at ¥3,859 million, up from ¥3,384 million in the previous fiscal year.
  13. FY2022-Q3AdvancedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥2,815 million.」

    Ongoing research and development spending was disclosed at ¥2,815 million for the current third-quarter cumulative period.
  14. FY2022-Q2AdvancedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥1,746 million.」

    Research and development expenses increased from ¥1,682 million in the same period of the previous year to ¥1,746 million, with ongoing research and development spending disclosed.
  15. FY2021-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥1,682 million.」

    Ongoing research and development spending was disclosed at ¥1,682 million for the current second-quarter cumulative period.
  16. FY2021-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥843 million.」

    Ongoing research and development spending was disclosed at ¥843 million.
  17. FY2020-Q3RestatedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥2,141 million.」

    Ongoing research and development spending was disclosed together with the cumulative amount.
  18. FY2020-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥1,359 million.」

    Ongoing research and development spending was disclosed at ¥1,359 million for the current second-quarter cumulative period.
  19. FY2020-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥659 million.」

    Ongoing research and development spending was disclosed together with the amount for the quarter.
  20. FY2019RestatedAnnual report

    「Research and development expenses for the current fiscal year for the Group as a whole were ¥2,899 million.」

    Ongoing research and development spending was disclosed together with the full-year cumulative amount.
  21. FY2019-Q3RestatedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥2,098 million.」

    Research and development spending continued to be disclosed together with the amount.
  22. FY2019-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥1,401 million.」

    Ongoing research and development spending was disclosed together with the cumulative amount.
  23. FY2019-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥692 million.」

    Ongoing research and development spending was disclosed together with the amount.
  24. FY2018-Q3RestatedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥2,164 million.」

    Research and development spending continued to be disclosed together with the amount.
  25. FY2018-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥1,426 million.」

    Ongoing research and development spending was disclosed together with the cumulative amount.
  26. FY2018-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥695 million.」

    Ongoing research and development spending was disclosed together with the amount.
  27. FY2017-Q3RestatedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥1,934 million.」

    Research and development spending continued to be disclosed together with the amount.
  28. FY2017-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥1,270 million.」

    Ongoing research and development spending was disclosed together with the amount.
  29. FY2017-Q1.Annual report

    「Total R&D expenses for the nine-month period ended the first quarter were ¥623 million.」

    Total R&D expenses for the quarter were disclosed.
Moved together

"Significant revenue growth in the Functional Colorants segment" moved the same way as this thread, in the same document, in 9 of its 29 moves.

999777★123456
  1. ★This thread
  2. 1Significant revenue growth in the Functional Colorants segment9×
  3. 2Increase in Cash Flow from Operating Activities9×
  4. 3Investment Expenditures from the Acquisition of Tangible and Intangible Fixed Assets9×
  5. 4Increase in Cash and Cash Equivalents7×
  6. 5Revenue growth in the Functional Resins segment7×
  7. 6Payment of Year-End Dividend7×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Hodogaya Chemical's next results are scheduled for 2026-11-11. Read the earnings preview It last moved in the Earnings of 2026-05-15: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.